Top Diclofenac Brands for Reliable Pain Relief

Diclofenac is a widely-used nonsteroidal anti-inflammatory drug (NSAID) known for its effectiveness in treating pain and inflammation. As its demand grows, numerous pharmaceutical brands have emerged, providing their own formulations of the medication. Some of the best and most trusted brands for diclofenac include [insert brand names here] due to their reliability and adherence to quality standards. To explore more about these brands and find the one that suits your needs, please see the comprehensive list below.

Illustration of diclofenac

Best brands of diclofenac in 2025

Voltaren

Voltaren, a leading brand in the diclofenac market, is renowned for its effective pain relief products, particularly its Arthritis Pain Gel, which is the first full prescription strength OTC topical NSAID gel for arthritis pain. The global Voltaren market is projected to reach USD 7513.99 million by 2031, growing at a CAGR of 4.50% from 2024 to 2031, with North America holding over 40% of the global revenue in 2024. Voltaren's products, such as the Emulgel(tm) formulation, penetrate deep into the skin to relieve arthritis pain, making it a trusted choice for over 10 years. The brand's dominance is also supported by its strong distribution networks, including online platforms, which are growing at the highest CAGR in the market. With a proven safety profile and clinical efficacy, Voltaren remains a top preference for managing chronic pain conditions.

Cataflam

Cataflam, a brand of diclofenac potassium immediate-release tablets, is a leading product in the global diclofenac market, which is projected to grow from USD 4.2 billion in 2023 to USD 6.4 billion by 2033 with a CAGR of 4.3%. Cataflam is widely used for treating pain or inflammation caused by arthritis, with recommended dosages ranging from 50 mg to 200 mg per day depending on the condition. The oral administration route, which Cataflam utilizes, dominates the market with a significant share, highlighting its ease of use and effectiveness. In 2021, the oral segment held a dominant market share, and Cataflam's formulation as immediate-release tablets contributes to this trend. The Asia-Pacific region, which holds a 35.5% market share, is also a key market for Cataflam due to robust medical infrastructure and increasing demand. For more detailed information, you can visit the Cataflam information page.

Zorvolex

Zorvolex, a brand of diclofenac, is distinguished by its use of proprietary SoluMatrix Fine Particle Technology(tm), which reduces the particle size of diclofenac to approximately 20 times smaller than its original size, enhancing dissolution and efficacy. Approved by the FDA in August 2014, Zorvolex is indicated for the management of osteoarthritis pain and mild to moderate acute pain in adults, with a dosage of 35mg orally three times daily for osteoarthritis. In a 12-month, open-label Phase 3 study, Zorvolex was found to be generally well tolerated and improved health-related quality of life (HRQOL) in patients with osteoarthritis pain, with 49.8% of patients remaining on the 35mg twice daily dosing regimen. Zorvolex has received recognition, including being shortlisted in the Best New Drug category for the 10th Annual SCRIP Awards in 2014. It is part of a market segment that held a dominant share in North America, with the diclofenac market projected to grow at a CAGR of 3.9% from 2022 to 2027. To learn more about Zorvolex, visit their official website.

Cambia

Cambia, a brand of diclofenac potassium, is a leading prescription strength NSAID approved by the FDA for the acute treatment of migraine, offering rapid peak absorption within 15 minutes, which is significantly faster than conventional diclofenac tablets. In clinical trials, Cambia demonstrated a 46% pain relief rate within two hours, outperforming diclofenac 50 mg pills and placebo. Approved in 2009, Cambia has shown efficacy in reducing migraine symptoms, including nausea, photophobia, and phonophobia. It is particularly beneficial for early intervention, with 24.7% of patients achieving pain-free status two hours post-dose. This formulation is preferred by patients seeking non-triptan options for headache relief. For more detailed information about Cambia's history and development, you can visit the Drugs.com page on Cambia.

Pennsaid

PENNSAID, a brand of diclofenac sodium topical solution, is a leading product in the treatment of osteoarthritis of the knee, boasting an estimated annual sales of USD 509 million in the U.S. as of 2022. It is available as a 2% w/w solution and has gained popularity due to its efficacy in managing pain and inflammatory symptoms. The product is integral to the broader diclofenac market, which is projected to grow from USD 4.2 billion in 2023 to USD 6.4 billion by 2033, with a CAGR of 4.3%. Osteoarthritis indications account for 37.5% of diclofenac usage, underscoring the significance of PENNSAID in this therapeutic area. The solution is favored for its faster absorption rates and is especially suitable for patients with difficulties in taking oral medications. For more detailed information, visit their official drug information page.

Flector

The Flector brand, known for its diclofenac epolamine topical system 1.3%, stands out as a leading producer in the diclofenac market. This product, manufactured by IBSA Group, offers targeted topical pain relief with significant pain reduction within 4 hours and sustained relief for 7 days with twice-a-day application. It is notable for its low systemic exposure and fast-acting properties, making it a preferred choice for patients. The Flector patch is an authorized generic, providing a cost-effective alternative to brand-name products while maintaining the same efficacy. This formulation has contributed to the growth of the diclofenac market, particularly in the topical segment. For more details, visit their Flector patch information page.

Arthrotec

Arthrotec, a brand name combination product of diclofenac sodium and misoprostol, is a leading treatment for the signs and symptoms of osteoarthritis or rheumatoid arthritis, particularly in patients at high risk of NSAID-induced gastric and duodenal ulcers. Approved by the FDA in 1997, Arthrotec has been a significant player in the market, with generic versions approved since 2012, including those from manufacturers like Watson (now part of Actavis) and others. The product protects the stomach while providing anti-arthritis benefits, making it a preferred choice for many patients. In 2012, Arthrotec had total US sales of approximately $130 million, highlighting its market impact. The combination of diclofenac and misoprostol in Arthrotec addresses both pain and inflammation while minimizing gastrointestinal side effects.

AcuDial

AcuDial, though not specifically mentioned as a leading producer in the provided sources, can be contextualized within the broader diclofenac market. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), is widely used for managing pain and inflammatory disorders, with the global market projected to grow from USD 4.2 billion in 2023 to USD 6.4 billion by 2033, at a CAGR of 4.3%. Tablets, which are a dominant form of diclofenac, hold a 55.5% market share, and osteoarthritis indications account for 37.5% of diclofenac usage. The drug's effectiveness in reducing inflammation and pain, particularly in osteoarthritis, makes it a crucial component in pain management regimes. However, specific data on AcuDial as a producer is not available in the provided sources.

Trosicam

Trosicam, though not specifically mentioned as a leading brand in the provided sources, can be contextualized within the broader diclofenac market. Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID), plays a significant role in managing pain and inflammation, especially in conditions like osteoarthritis, which accounts for 37.5% of its usage. The global diclofenac market is projected to grow from USD 4.2 billion in 2023 to USD 6.4 billion by 2033, with a CAGR of 4.3%. Asia Pacific dominates this market with a 35.5% share valued at USD 1.5 billion. Tablets are the preferred form, holding a 55.5% market share due to their ease of use and precise dosage. The market's growth is driven by increasing healthcare expenditure and the rising awareness of pain management solutions. For further details, refer to the diclofenac market report.

Diclofex

Diclofenac, marketed under brands like Voltaren, is a widely used non-steroidal anti-inflammatory drug (NSAID) known for its efficacy in treating pain and inflammation. It is not specifically associated with a brand named "Diclofex," but major pharmaceutical companies like Novartis (previously Ciba-Geigy) have been prominent in its production and distribution. Diclofenac was first approved by the FDA in July 1988 and has since become one of the most commonly prescribed medications, with over 12 million prescriptions in the United States in 2022. It is available in various formulations, including oral, rectal, intramuscular, intravenous, topical, and ophthalmic routes. The drug's market is projected to grow at a CAGR of 3.9% from 2022 to 2027, reaching a market size of $6.1 billion by 2027. For further insights into the Diclofenac market trends, visit the IndustryARC website.